StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
Shares of NASDAQ RDHL remained flat at $0.45 during mid-day trading on Friday. 173,901 shares of the company traded hands, compared to its average volume of 350,921. RedHill Biopharma has a 12 month low of $0.26 and a 12 month high of $3.28. The business’s 50-day moving average price is $0.50 and its 200 day moving average price is $0.75.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in RedHill Biopharma stock. Sabby Management LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 635,006 shares of the biotechnology company’s stock, valued at approximately $324,000. RedHill Biopharma accounts for about 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 17th biggest holding. Sabby Management LLC owned approximately 5.74% of RedHill Biopharma at the end of the most recent reporting period. 7.20% of the stock is owned by hedge funds and other institutional investors.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Read More
- Five stocks we like better than RedHill Biopharma
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- MarketBeat Week in Review – 4/29 – 5/3
- Basic Materials Stocks Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The Most Important Warren Buffett Stock for Investors: His Own
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.